GoodRx Holdings

GDRX

Market cap $1.46B

Overview Fund Activity

4.19 USD

-0.03

0.71%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

4.22

+0.03

0.72%

1 day

-0.71%

5 days

4.75%

1 month

19.71%

3 months

-6.47%

6 months

-10.09%

Year to date

-8.11%

1 year

-45.73%

5 years

-91.7%

10 years

-91.7%

About: GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Employees: 738

Healthcare Health Information Services

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

188% more call options, than puts

Call options by funds: $4.01M | Put options by funds: $1.4M

59% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 22

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

12% more capital invested

Capital invested by funds: $536M [Q1] → $600M (+$63.4M) [Q2]

7% more funds holding

Funds holding: 165 [Q1] → 177 (+12) [Q2]

6.13% more ownership

Funds ownership: 113.94% [Q1] → 120.07% (+6.13%) [Q2]

20% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 66

See Fund Rankings

Financial journalist opinion

Based on 8 articles about GDRX published over the past 30 days

GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., is riding into new creative territory with the launch of The Savings Wrangler, a groundbreaking brand campaign that aims to bring the company's mission to life in an unforgettable way. Designed to deepen cultural relevance and brand resonance, the campaign introduces a lasso-wielding heroine – the Savings Wrangler – a lovable and fiercely dedicated cowgirl who's on a mission to.

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18th after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According to the companies' joint press release today, “all strengths of Ozempic and Wegovy are now available to eligible self-paying patients for $499/month through GoodRx.

Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing, driving a 30% stock surge and validating its business model. Pharma Manufacturer Solutions is growing 30%+ annually, boosting profitability and positioning GoodRx as a key player as drug pricing shifts to point-of-sale affordability. Despite headwinds like Rite Aid's bankruptcy and competition, GoodRx maintains strong margins, robust cash flow, and an undervalued multiple versus peers and history.

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy.

Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims

Proactive Investors

Novo Nordisk expands access to Ozempic, Wegovy through GoodRx and other platforms

Novo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the therapy for those who do not have insurance coverage. Patients can pay $499 in cash per month through the drug's website, Novo Nordisk's patient assistance program, the company's direct-to-consumer online pharmacy and via drug savings platform GoodRx.

Novo Nordisk expands access to Ozempic, Wegovy through GoodRx and other platforms

Bloomberg Markets and Finance

Novo Cuts Price of Ozempic in Half for Cash Buyers

Novo Nordisk A/S is slashing the cost of Ozempic for cash-paying patients to $499 a month through NovoCare and partnering with GoodRx Holdings Inc. to offer it at the same price at US pharmacies. Bloomberg's Madison Muller reports.

Novo Cuts Price of Ozempic in Half for Cash Buyers

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They're Offering Ozempic for $499 a Month.

GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.

GoodRx Stock Spikes 35% on Novo Nordisk Collaboration. They're Offering Ozempic for $499 a Month.

GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for.

GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

GoodRx Holdings, Inc. (GDRX) Q2 2025 Earnings Call Transcript

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Christopher A. McGinnis - CFO & Treasurer Wendy Barnes - President, CEO & Director Conference Call Participants Charles Rhyee - TD Cowen, Research Division Daniel R.

GoodRx Holdings, Inc. (GDRX) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

See News Rankings

Charts implemented using Lightweight Charts™